Edition:
United Kingdom

Galapagos NV (GLPG.OQ)

GLPG.OQ on NASDAQ Stock Exchange Global Select Market

102.67USD
17 Jul 2018
Change (% chg)

$0.97 (+0.95%)
Prev Close
$101.70
Open
$102.01
Day's High
$102.97
Day's Low
$101.74
Volume
10,066
Avg. Vol
34,880
52-wk High
$121.08
52-wk Low
$72.92

Latest Key Developments (Source: Significant Developments)

Galapagos FY Net Result Swings To Loss Of 115.7 Million Euros
Friday, 23 Feb 2018 

Feb 23 (Reuters) - GALAPAGOS ::REPORTED ON THURSDAY FY NET LOSS OF €115.7 MILLION, COMPARED TO NET PROFIT OF €54.0 MILLION IN 2016.FY GROUP REVENUES INCREASED BY €4.3 MILLION TO €155.9 MILLION.FY OPERATING LOSS INCREASED BY €78.3 MILLION TO €89.8 MILLION.FY OPERATIONAL CASH BURN OF €154.1 MILLION.CASH BALANCE INCREASED BY €171.5 MILLION TO €1,152.4 MILLION AT YEAR-END.IN 2018 AIMS TO REPORT TOPLINE RESULTS WITH THE FINCH 2 (RHEUMATOID ARTHRITIS), EQUATOR (PSORIATIC ARTHRITIS), TORTUGA (ANKYLOSING SPONDILITIS) FILGOTINIB TRIALS AS WELL AS A DECISION TO CONTINUE TO PHASE 3 IN SELECTION (ULCERATIVE COLITIS).IN 2018 COLLABORATION PARTNER GILEAD EXPECTS TO COMPLETE RECRUITMENT OF FINCH 1 AND FINCH 3, THE REMAINING RA PHASE 3 TRIALS WITH FILGOTINIB.IN 2018 IN CYSTIC FIBROSIS WE ANTICIPATE THE READOUT OF THE PELICAN PATIENT TRIAL AND AN INTERIM READOUT IN FALCON.IN 2018 AIMS TO INITIATE PIVOTAL TRIALS WITH GLPG1690 (IPF) AND PHASE 2 TRIALS WITH GLPG1205 (IPF), AN ADDITIONAL CF TRIPLE COMBINATION, GLPG1972 (OSTEOARTHRITIS), AND MOR106 (ATOPIC DERMATITIS).EXPECTS AN OPERATIONAL CASH BURN BETWEEN €220 AND €240 MILLION IN 2018.  Full Article

Morphosys And Galapagos Present Results From Phase 1 Study With Mor106
Monday, 19 Feb 2018 

Feb 19 (Reuters) - MORPHOSYS AG ::SAID ON SATURDAY MORPHOSYS AND GALAPAGOS PRESENT RESULTS FROM A PHASE 1 STUDY WITH MOR106 IN ATOPIC DERMATITIS AS LATE-BREAKING ABSTRACT.IN THE STUDY, MOR106 WAS GENERALLY WELL TOLERATED IN ATOPIC DERMATITIS(AD)PATIENTS.83% OF PATIENTS (5 OUT OF 6) AT THE HIGHEST DOSE REACHED AT LEAST 50% IMPROVEMENT PER THE ATOPIC DERMATITIS AREA AND SEVERITY INDEX (EASI-50) AT WEEK 4.POOLED DATA ACROSS ALL DOSE COHORTS SHOWED 72% IMPROVEMENT OF AD SYMPTOMS AT WEEK 12 COMPARED TO BASELINE IN PATIENTS TREATED WITH MOR106.PHASE 2 DEVELOPMENT OF MOR106 PLANNED TO BE INITIATED IN FIRST HALF OF 2018.  Full Article

ProQR And Galapagos Announce Research Collaboration
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Galapagos Nv ::PROQR AND GALAPAGOS ANNOUNCE RESEARCH COLLABORATION ON FIBROSIS TARGETS USING PROQR’S AXIOMER® TECHNOLOGY.PROQR THERAPEUTICS - UNDER AGREEMENT, TWO COMPANIES WILL WORK TOGETHER TO DISCOVER NOVEL AXIOMER EONS AGAINST FIBROSIS TARGETS SELECTED BY GALAPAGOS.PROQR THERAPEUTICS NV- TARGETS THAT WILL BE PURSUED IN COLLABORATION AND FINANCIAL DETAILS ABOUT COLLABORATION ARE NOT DISCLOSED.  Full Article

Galapagos NV reports Q3 loss of ‍1.75​ euro per share
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Galapagos NV -:Galapagos NV qtrly ‍revenues 106.4 million euro versus 65 million euro​.Galapagos NV qtrly loss per share ‍1.75​ euro.Galapagos NV says ‍we anticipate cash burn for full year to be at lower end of guidance of euro 135 million - 155 million​.  Full Article

Galapagos says GLPG1690 halts disease progression in IPF patients in mid-stage trial
Wednesday, 9 Aug 2017 

Aug 9 (Reuters) - Galapagos Nv :GLPG1690 halts disease progression in IPF patients in Flora phase 2A trial.Galapagos NV says GLPG1690 was generally well tolerated.Galapagos NV - ‍GLPG1690 expected to progress to late stage trial​.Galapagos NV -‍ rates of discontinuation due to adverse events, as well as serious adverse event rates, were similar between patients on GLPG1690, placebo​.  Full Article

Galapagos confirms FY cash burn guidance within range of €135 mln to €155 mln
Monday, 31 Jul 2017 

July 31 (Reuters) - Galapagos Nv -:Galapagos NV says confirm cash burn guidance for the full year within the range of € 135 million – € 155 million - sec filing.  Full Article

Galapagos H1 revenues up at EUR 73.0 mln
Friday, 28 Jul 2017 

July 28 (Reuters) - GALAPAGOS ::ANNOUNCED ON THURSDAY H1 REVENUES EUR 73.0 MLN VS EUR 48.8 MLN YEAR AGO.H1 OPERATING LOSS EUR 32.9 MLN VS LOSS OF EUR 24.3 MLN YEAR AGO.H1 NET LOSS EUR 49.2 MLN VS PROFIT OF EUR 32.2 MLN YEAR AGO.CASH POSITION AT JUNE 30 EUR 1.26 BLN VS EUR 968.5 MLN YEAR AGO.CONFIRMS CASH BURN GUIDANCE FOR THE FULL YEAR WITHIN THE RANGE OF EUR 135–155 MILLION.  Full Article

Servier announces it has exercised option to develop osteoarthritis molecule from Galapagos
Thursday, 27 Jul 2017 

July 27 (Reuters) - GALAPAGOS NV ::SERVIER ANNOUNCES IT HAS EXERCISED OPTION TO DEVELOP NOVEL OSTEOARTHRITIS MOLECULE GLPG1972/S201086 FROM GALAPAGOS NV, OBTAINING GLOBAL COMMERCIAL RIGHTS OUTSIDE THE U.S..TO RECEIVE €6 MILLION LICENSE FEE FROM SERVIER AND ELIGIBLE TO TOTAL OF €290 MILLION IN SUCCESS-BASED MILESTONES FROM COLLABORATION.  Full Article

Galapagos says share capital increase arising from warrant exercises
Wednesday, 21 Jun 2017 

June 20 (Reuters) - Galapagos Nv ::Announces a share capital increase arising from warrant exercises..Issued 52,030 new ordinary shares on 20 June 2017, for a total capital increase of 631,898.90 euros..  Full Article

Galapagos announces successful completion of Phase 1
Tuesday, 20 Jun 2017 

June 20 (Reuters) - Galapagos nv :GALAPAGOS' RESEARCH AND DEVELOPMENT UPDATE 2017: RAPIDLY ADVANCING OUR PRODUCT CANDIDATES.CYSTIC FIBROSIS: START OF REGULATORY PROCESS NEXT MONTH, PATIENT STUDY WITH FIRST TRIPLE COMBO EXPECTED TO BEGIN IN Q4 '17 IN EUROPE‍​.ON FILGOTINIB: DARWIN 3: IMPROVED ACTIVITY, CONSISTENT SAFETY PARAMETERS FOR FILGOTINIB; PH2 STUDIES INITIATED IN 6 NEW INDICATIONS.TOPLINE DATA FOR GLPG1690 IN IPF IN Q3 '17.OPENING OF US IND AND DOSING OF FIRST OSTEOARTHRITIS PATIENT IN PHASE 1B TRIAL WITH GLPG1972.CYSTIC FIBROSIS: SUCCESSFUL COMPLETION OF PH1 WITH THREE INDIVIDUAL COMBO COMPONENTS‍​.  Full Article

US STOCKS-Wall Street ekes out gain as Nike surges

* Indexes up: Dow 0.2 pct, S&P 0.1 pct, Nasdaq 0.1 pct (Updates to close)